LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.

被引：0
|
作者：
Kwiatek, Michal
Carlo-Stella, Carmelo
Urban, Andrzej
Niewiarowski, Andrew
Wang, Luqiang
Hamadani, Mehdi
机构：
[1] Ctr Med Pratia Poznan, Skorzewo, Poland
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Humanitas Univ, Dept Hematol & Oncol, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Milan, Italy
[5] ADC Therapeut SA, Epalinges, Switzerland
[6] ADC Therapeut Ltd, London, England
[7] ADC Therapeut Amer Inc, Murray Hill, NJ USA
[8] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7097
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
    Sehn, Laurie Helen
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
    Trneny, Marek
    Leonard, John P.
    Zhang, Huilai
    Nowakowski, Grzegorz
    Izutsu, Koji
    Fowler, Nathan H.
    Thieblemont, Catherine
    Zinzani, Pier Luigi
    Kalambakas, Stacey
    Czuczman, Myron
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    BLOOD, 2019, 134
  • [33] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
  • [34] RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.
    Fowler, Nathan Hale
    Morschhauser, Franck
    Feugier, Pierre
    Bouabdallah, Reda
    Tilly, Herve
    Palomba, Maria Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Hertzberg, Mark
    Ku, Matthew
    Catalani, Olivier
    Althaus, Betsy
    Simko, Stephen
    Gregory, Gareth P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abe
    Avery, E. J.
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2020, 61 : 235 - 237
  • [37] First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa plus lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.
    Belada, David
    Kopeckova, Katerina
    Bergua, Juan Miguel
    Andre, Marc
    Persona, Ernesto Perez
    Pichler, Petra
    Klopfer, Pia
    Brackertz, Bettina
    Lohrmann, Emanuel
    Lahiry, Anirban
    Shah, Neha
    Brugger, Wolfram
    Burke, John M.
    Nowakowski, Grzegorz S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Phase 3 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
    Sehn, Laurie Helen
    Chamuleau, Martine
    Lenz, Georg
    Clausen, Michael
    Haioun, Corinne
    Izutsu, Koji
    Davies, Andrew John John
    Zhu, Jun
    Oki, Toshiko
    Szafer-Glusman, Edith
    Conlon, Rebekah
    Chiou, Hueiyu
    Ipe, David
    Elliott, Brian
    Wu, Jun
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
    Sehn, Laurie H.
    Hertzberg, Mark
    Opat, Stephen
    Herrera, Alex F.
    Assouline, Sarit
    Flowers, Christopher R.
    Kim, Tae Min
    McMillan, Andrew K.
    Ozcan, Muhit
    Safar, Violaine
    Salles, Gilles
    Hirata, Jamie
    Yang, Annie
    Musick, Lisa
    Matasar, Matthew J.
    BLOOD, 2022, 140 : 9464 - 9467
  • [40] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
12345